Abstract:
The present invention relates to a composition for treating or preventing inflammatory diseases. The present invention provides a pharmaceutical composition for preventing or treating inflammatory diseases, which comprises a Myagropsis myagroides extract or a fraction of the extract as an active ingredient. The Myagropsis myagroides extract or the fraction thereof does not contain known existing fucoxanthin but controls the generation of nitrogen monoxide (NO), prostaglandin E_2 (PGE_2) and inflammatory cytokines and also controls the expression of iNOS and COX-2 effectively so that the pharmaceutical composition can be used usefully for preventing and treating inflammatory diseases. [Reference numerals] (AA) Myagropsis myagroides; (BB) Sun drying; (CC) Extraction by reflux condensing (Repeat three times); (DD) Powder; (EE) Extract; (FF) Vaccum filtration; (GG) Vacuum rotating concentration/40°C (solvent removal); (HH) Crude extract; (II) Myagropsis myagroides crude extract; (JJ) Organic solvent soluble fractioning (Repeat 3-4 times); (KK) n-hexane soluble fraction; (LL,NN,PP,RR) Water soluble fraction; (MM) Dichloromethane soluble fraction; (OO) Ethyl acetate soluble fraction; (QQ) n-butanol soluble fraction
Abstract:
PURPOSE: A composition containing Ecklonia stolonifera or Ecklonia cava spirit extract is provided to suppress tyrosinase expression and melanogenesis. CONSTITUTION: A composition with a whitening effect contains Ecklonia stolonifera spirit extract as an active ingredient. The Ecklonia stolonifera spirit extract is used as a material for a cosmetic product for skin whitening, a pharmaceutical product for treating hyperpigmentary dermatitis, and a functional food for whitening. The composition also contains Ecklonia cava spirit extract as an active ingredient. The composition additionally contains dieckol or phlorofucofuroeckol A as an active ingredient. [Reference numerals] (AA) Ecklonia stolonifera/Ecklonia cava; (BB) Drying in the shade; (CC) Powder; (DD) - reflux condensing extraction(repeat three times) - using spirit; (EE) Extraction; (FF) Filtering by reduced pressure; (GG) - vacuum rotary concentration - 40°C(removing organic solvent); (HH) Ecklonia stolonifera/Ecklonia cava crude extract; (II) Organic solvent soluble fraction(repeat 3-4 times); (JJ) N-hexane soluble extract; (KK) Water soluble fraction; (LL) Dichloromethane soluble extract; (MM) Water soluble fraction; (NN) Ethyl acetate soluble extract; (OO) Water soluble fraction
Abstract:
PURPOSE: A composition containing Ecklonia stolonifera OKAMURA and ecklonia cava extract is provided to suppress iNOS and COX-2 expression. CONSTITUTION: A composition for suppressing inflammation contains Ecklonia stolonifera OKAMURA and ecklonia cava extract. The composition contains hexane extract of Ecklonia stolonifera OKAMURA and ecklonia cava using water, low alcohol or mixture solvent. A pharmaceutical composition or functional food composition for suppressing inflammation contains phlorotannin isolated and purified from crude extract or non-polar solvent soluble extract of Ecklonia stolonifera OKAMURA and ecklonia cava. A pharmaceutical composition contains phlorofucofuroeckol A compound as an active ingredient.
Abstract:
본발명은톱니모자반추출물을유효성분으로포함하는관절염예방또는치료용조성물에관한것이다. 본발명은톱니모자반추출물을유효성분으로포함하는관절염예방또는치료용조성물에관한것이다. 본발명에따른톱니모자반추출물은염증성사이토카인 IL-1β, IL-6 또는 TNF-a의활성을감소또는억제시키는활성이우수하고, 관절염동물모델에서관절염을개선하는효과가우수하여관절염치료용조성물로유용하게사용할수 있다. 또한, 세포독성이일어나지않으며, 약물에대한독성및 부작용도없어장기간복용시에도안심하고사용할수 있으며, 체내에서도안정한효과가있다.